Drug Profile

Baricitinib - Eli Lilly and Company/Incyte Corporation

Alternative Names: INCB 028050; INCB 28050; LY 3009104; Olumiant

Latest Information Update: 03 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation; Natco Pharma
Class Acetonitriles; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azetidines; Eye disorder therapies; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Systemic lupus erythematosus
New Molecular Entity Yes

Marketed Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
Registered COVID 2019 infections
Phase III Juvenile rheumatoid arthritis; Uveitis
Phase II/III Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
Discontinued Diabetic nephropathies; Primary biliary cirrhosis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus

30 Oct 2025 Eli Lilly and Company plans a phase III trial for Type I diabetes mellitus (Treatment naive, In infants, In children, In adolescents, In adults) in Australia, Belgium, Brazil, Canada, Czech Republic, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Ukraine, United Kingdom, USA (PO) (NCT07222332)
29 Oct 2025 Eli Lilly and Company plans a phase III (BARICADE-DELAY) trial for Type 1 diabetes mellitus (In infants, In children, In adolescents, In adults) in the USA, Australia, Belgium, Brazil, Canada, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom (PO) (NCT07222137)
08 Mar 2025 The efficacy and adverse event data from a phase III BRAVE-AA-PEDS trial in Alopecia areata released by Eli Lilly and Company

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com